Chinese pharmaceutical company Triastek developed a 3D-printed drug, T19, to treat rheumatism. The geometric structures and shapes of the drug contribute to far-reaching control of how the drug is developed. The print technique thereby increases effectiveness and reduces side effects. Patients ingest the drug before they go to sleep and the release of active ingredients into the body is delayed. As a result, the drug takes effect in the morning, which is when patients experience the most severe pain. The drug was approved by the American FDA early 2021.
